AAIC 2026: Combination Therapy and Multi-Target Approaches in Alzheimer's Disease
Conference: Alzheimer's Association International Conference (AAIC) 2026
Dates: July 12-15, 2026
Location: ExCeL London, UK
Theme: Building Bridges in Alzheimer's Research
Executive Summary
Mermaid diagram (expand to render)
The approval of [lecanemab](/therapeutics/lecanemab) (Leqembi) and [donanemab](/therapeutics/donanemab) (Kisunla) has transitioned Alzheimer's disease from a single-target era into a combination therapy paradigm. At AAIC 2026, the EU/US CTAD Task Force highlighted combination therapy as the central strategic priority for the next decade of AD drug development["@ctad2025"]. As of early 2026, the AD drug development pipeline includes 24 combination therapy trials, representing the largest growth sector in the field["@cummings2025"].
This page covers the scientific rationale, active clinical programs, trial design considerations, and regulatory landscape for combination approaches in Alzheimer's disease.
Scientific Rationale for Combination Therapy
Why Single-Target Approaches Are Insufficient
[Alzheimer's disease](/diseases/alzheimers-disease) involves multiple concurrent pathological processes, and targeting only one mechanism has proven insufficient for robust disease modification[@rochfort2023][@huang2022]:
- Protein aggregation: [Amyloid-beta](/proteins/amyloid-beta) plaques, [tau](/proteins/tau) neurofibrillary tangles, and their oligomeric intermediates drive distinct but interacting pathways
- Neuroinflammation: Activated [microglia](/cell-types/microglia), [reactive astrocytes](/cell-types/reactive-astrocytes-overview), and the [complement system](/mechanisms/complement-system-pathway) contribute to synaptic loss independent of amyloid
- Synaptic dysfunction: Network disruption and interneuron dysfunction occur early and progress even after amyloid clearance[@palop2016]
- Metabolic dysregulation: Insulin resistance, lipid dysmetabolism, and mitochondrial dysfunction create a permissive environment for pathology
- Vascular dysfunction: Blood-brain barrier breakdown and cerebral hypoperfusion compound neuronal injury[@chen2023]
The EU/US CTAD Task Force has formally concluded that monotherapy — even with the most effective anti-amyloid agents — cannot address the full complexity of AD, and that combination strategies are necessary to achieve the level of disease modification required for meaningful clinical impact[@scheltens2021][@milton2021].
Pharmacological Interactions: Synergy, Additivity, and Antagonism
Combination therapy can produce three types of interaction[@huang2022][@zhang2022]:
- Synergistic: Combined effect exceeds the sum of individual effects. Example: [anti-amyloid antibodies](/therapeutics/anti-amyloid-immunotherapy) + [TREM2](/proteins/trem2-protein) agonists may synergize because amyloid clearance requires functional, non-hyper-activated microglia to clear debris
- Additive: Combined effect equals the sum of individual effects. Example: disease-modifying agents + symptomatic treatments addressing independent disease dimensions
- Antagonistic: Combined effect is less than expected — a critical risk requiring factorial trial designs to detect
Lessons from Oncology and Infectious Disease
The success of combination therapy in cancer (checkpoint inhibitors + chemotherapy + targeted therapy) and HIV (triple antiretroviral therapy — HAART) provides a strong precedent[@cummings2024][@simmons2023]:
- In both fields, monotherapy led to resistance or escape; multi-target approaches were necessary for durable disease control
- Cancer therapy evolved from single-agent chemotherapy to rational combinations based on molecular profiling
- Neurodegeneration is following a similar trajectory, with [biomarker-guided patient stratification](/therapeutics/biomarker-guided-therapy) enabling personalized combination selection
Anti-Amyloid + Anti-Tau Combinations
The Scientific Rationale
The anti-amyloid + anti-tau combination is the conceptually most compelling strategy, targeting both hallmark pathologies of AD[@kaur2023][@simmons2023]:
- [Amyloid-beta](/mechanisms/amyloid-cascade) drives the initiation phase of AD, but tau pathology correlates more closely with clinical decline and cognitive progression
- Clearing amyloid alone does not halt [tau spreading and propagation](/mechanisms/tau-seeding-propagation); tau pathology can advance even after amyloid is cleared
- The two pathologies interact through multiple mechanisms: amyloid-induced microglial activation promotes tau phosphorylation; tau aggregates can accelerate amyloid deposition; both contribute to synaptic loss through distinct mechanisms
Clinical Trial Programs
The DIAN-TU is the leading platform for testing anti-amyloid + anti-tau combinations in genetic forms of AD:
- Study Design: 2x2 factorial trial testing anti-amyloid (lecanemab or semorinemab) + anti-tau (E2814, a tau ASO) in autosomal dominant AD mutation carriers
- Rationale: Genetic certainty and predictable disease course enable smaller trials with shorter follow-up
- Primary Endpoints: Biomarker changes (CSF tau, amyloid PET) and cognitive measures
- Status: Active enrollment, results anticipated 2026-2027
Tau ASO + Anti-Amyloid Combinations
The E2814 tau ASO (developed by Ionis and Eisai) targets the MAPT gene to reduce tau production:
- Phase 1/2: E2814 monotherapy demonstrated CSF tau reduction with acceptable safety
- Combination: DIAN-TU is testing E2814 + lecanemab; results expected at AAIC 2026
- Mechanism: Reducing tau synthesis may synergize with amyloid clearance to prevent downstream neurodegeneration[@tahami2024]
Anti-Tau Antibodies + Anti-Amyloid Antibodies
Multiple programs are testing anti-tau antibodies in combination with approved anti-amyloid agents:
| Combination | Company | Phase | Status |
|---|---|---|---|
| Semorinemab + lecanemab | Roche/Genentech | Phase 2 | Planning |
| E2814 + lecanemab | Ionis/Eisai | Phase 1/2 (DIAN-TU) | Enrolling |
| Zagotenemab + donanemab | Eli Lilly | Phase 2 | Planning |
Biomarker Considerations for Anti-Amyloid + Anti-Tau
Monitoring combinations requires tracking both pathologies independently:
- Amyloid PET or plasma [p-tau217](/biomarkers/p-tau-217) for amyloid target engagement
- Tau PET ([Fluoropyridine](/proteins/fluoropyridine) or [MK-6240](/proteins/mk-6240)) for tau burden
- CSF p-tau181/t-tau for longitudinal monitoring
- Neurofilament light chain (NfL) for neurodegeneration progression
- Cognitive endpoints: CDR-SB, ADAS-Cog14, integrated AD score
Anti-Amyloid + Anti-Inflammatory Combinations
Rationale
[Neuroinflammation](/mechanisms/neuroinflammation) accelerates disease progression independent of amyloid, and the neuroinflammatory response to amyloid clearance may limit the benefit of anti-amyloid monotherapy[@wang2024][@bartels2023]:
- Activated microglia drive synaptic pruning through the [complement cascade](/mechanisms/complement-system-pathway), causing synapse loss even after plaques are cleared
- The [NLRP3 inflammasome](/mechanisms/nlrp3-inflammasome) in microglia releases IL-1beta and other pro-inflammatory cytokines that promote tau pathology
- Reactive astrocytes adopt neurotoxic A1 phenotype, releasing toxic factors that kill neurons
- Blood-brain barrier dysfunction allows peripheral immune cells to infiltrate the CNS
TREM2 Agonists as Combination Partners
[TREM2](/proteins/trem2-protein) agonists represent the most advanced anti-inflammatory approach for combination with anti-amyloid therapy[@wang2024]:
| Program | Company | Mechanism | Phase |
|---|---|---|---|
| AL002 | Alector/AbbVie | Anti-TREM2 agonistic antibody | Phase 2 (INVOKE-2) |
| PY314 | Pyroneer/Takeda | TREM2 agonist | Phase 1 |
| HFF223 | Honce/Takeda | TREM2 agonist | Preclinical |
Mechanism: TREM2 signaling promotes microglial survival, proliferation, and beneficial phagocytosis. TREM2 agonism may:
Enhance amyloid plaque clearance when combined with anti-amyloid antibodies
Shift microglia from disease-associated (DAM) to homeostatic state
Reduce complement-mediated synaptic pruning
Decrease NLRP3 inflammasome activationAAIC 2026 expected updates: Phase 2 AL002 (INVOKE-2) results in TREM2 variant carriers, with planned combination cohorts with anti-amyloid agents.
Complement Inhibitors
The [complement system](/mechanisms/complement-system-pathway) is a compelling target for combination because complement-mediated synaptic pruning continues even after amyloid clearance[@bartels2023]:
| Program | Company | Target | Phase |
|---|---|---|---|
| ANX005 (anifrolumab) | Annexon | Anti-C1q | Phase 1b/2 |
| ABvac-40 | Araclon | Anti-A beta 40 | Phase 1 |
| CT0550 | ClearPath | Complement modulator | Preclinical |
Rationale: ANX005 (anti-C1q) combined with anti-amyloid therapy may reduce synaptic complement-mediated pruning that continues even after amyloid clearance. Phase 1b data showed good safety and biomarker target engagement; Phase 2 combination study with lecanemab is planned.
GLP-1 Receptor Agonist Combinations
[GLP-1 receptor agonists](/therapeutics/glp1-receptor-agonists) address metabolic dysfunction and neuroinflammation through orthogonal mechanisms, making them logical combination partners:
- Semaglutide in the EVOKE Plus trial (3-year, 1,800+ patients) for early AD
- Liraglutide Phase 2b (ELAD trial) showed ~50% reduction in brain volume loss and up to 18% slower cognitive decline
- Combination potential: GLP-1 agonists address metabolic dysfunction, neuroinflammation, and insulin resistance — pathways orthogonal to anti-amyloid and anti-tau therapies[@kaur2023]
Multi-Target-Directed Ligands (MTDLs)
An alternative to multi-drug combinations is the design of single molecules that hit multiple targets[@huang2022]:
Classes of MTDLs
- Dual AChE/MAO-B inhibitors: Ladostigil and ASS234 combine cholinesterase inhibition with monoamine oxidase inhibition in a single molecule
- Metal chelator-antioxidant hybrids: M30 and HLA20 combine iron chelation with radical scavenging and MAO inhibition — triple-action molecules for PD
- Anti-aggregation/anti-inflammatory hybrids: Single molecules that inhibit [amyloid-beta](/proteins/amyloid-beta) aggregation while simultaneously modulating NF-kappaB-mediated inflammation
- A3 subtype-selective muscarinic agonists: Designed to simultaneously activate M1 receptors (cognitive) and antagonize M2 receptors (neuroprotection)
Advantages and Challenges
Advantages:
- Simplified pharmacokinetics — no drug-drug interactions
- Improved patient compliance (single pill vs. multiple agents)
- Synergistic multi-target effects from single molecule
- No regulatory complexity of combination product classification
Challenges:
- Achieving balanced potency across multiple targets
- Regulatory pathway uncertainty (novel compound vs. combination product)
- May not achieve the specificity of targeted biologics
Cell-Type-Directed Network-Correcting Combinations
A landmark 2024 Cell publication introduced a data-driven approach to combination therapy design using cell-type-specific transcriptomic networks[@simmons2023]:
The SEA-AD Approach
Approach: Integrated single-cell transcriptomics from SEA-AD and Allen Brain Cell Atlas with drug perturbation databases and electronic medical records from 1.4 million adults aged 65+ across six University of California health systems[@bartels2023]
Identified combination: Letrozole (aromatase inhibitor, used for breast cancer) targeting disease-associated gene expression in glial cells + irinotecan (topoisomerase inhibitor, used for colon/lung cancer) targeting neuronal disease networks
Preclinical results:
- In an AD mouse model with both amyloid and tau pathology, letrozole + irinotecan significantly improved memory performance
- Single-nucleus transcriptomic analysis confirmed cell-type-specific network reversal
- EMR analysis showed prior exposure to either drug was associated with lower AD incidence after propensity-matched adjustment
AAIC 2026 expected updates: Validation studies in human tissue, biomarker correlates, and planning for Phase 1/2 trials.
Clinical Trial Design for Combinations
Factorial Designs
The gold standard for testing combination contributions is the 2x2 factorial design[@huang2022]:
Drug B
Placebo Active
Placebo Placebo Drug B alone
A Drug A Both drugs
alone
This design allows:
- Independent assessment of each agent
- Detection of synergistic vs. additive effects
- Efficient sample size vs. four separate trials
Challenge: Requires 4x the sample size of a simple two-arm trial.
Platform trials enable efficient testing of multiple combinations with shared control arms[@epelbaum2025]:
- DIAN-TU: Multi-arm platform testing anti-amyloid + anti-tau combinations
- GBM AGILE: Adaptive platform for brain disorders, enabling arm addition/dropping
- I-SPY-ALZ: Bayesian adaptive platform optimizing combination regimens
Biomarker-Enriched Designs
Biomarker-driven patient selection maximizes signal detection[@cummings2025]:
- Amyloid-positive + tau-positive: Required for anti-amyloid + anti-tau combinations
- Inflammatory marker elevation: YKL-40, GFAP, or IL-6 for anti-inflammatory combination selection
- Genetic stratification: [APOE4](/proteins/apoe-protein) carriers may have differential response to combinations
Basket Trials
Testing the same combination across multiple neurodegenerative diseases that share mechanisms:
- Anti-amyloid + anti-inflammatory combinations in AD, [PD](/diseases/parkinsons-disease), and [PSP](/diseases/progressive-supranuclear-palsy)
- Leverages common neuroinflammatory pathways across diseases
Phase-Specific Combination Strategies
| Phase | Strategy | Rationale |
|-------|---------|-----------|
| Phase 1 | Monotherapy dose-finding | Establish safety of individual components first |
| Phase 2 | Two-drug combination | Test synergy, identify optimal dose combinations |
| Phase 3 | Phase 2-optimal combination | Confirm efficacy with validated regimen |
Regulatory Considerations for Combination Therapies
Classification as Combination Products
A critical regulatory question is whether a combination constitutes a "combination product" under FDA regulations or is simply two separate drugs used together[@epelbaum2025]:
- Fixed-dose combinations (single pill with two agents): Likely treated as a combination product, requiring single NDA
- Separate co-administered drugs: Each retains its own regulatory pathway; no combined approval needed
- Sequential therapy: Separate approvals for each phase of treatment
Accelerated Approval Pathway
The FDA's accelerated approval pathway is particularly relevant for combinations[@cummings2025]:
- Biomarker endpoints can serve as surrogate endpoints for approval if reasonably likely to predict clinical benefit
- Plasma p-tau217 as an acceptable endpoint for combinations targeting amyloid + tau
- Combined cognitive + biomarker endpoints increasingly accepted
International Regulatory Landscape
- EMA adaptive trial designs: European Medicines Agency has shown flexibility for combination product approval
- Japan PMDA: Has fast-tracked several combination programs for AD
- ICH harmonization: Ongoing efforts to align combination therapy regulatory requirements across jurisdictions
Specific Active Combination Trials
Anti-Amyloid + Anti-Inflammatory
| Trial | Agents | Phase | Patients | Primary Endpoint | Status |
|-------|--------|-------|----------|-----------------|--------|
| INVOKE-2 | AL002 + lecanemab | Phase 2 | 300 | Biomarker + cognitive | Enrolling |
| AL002-001 | AL002 monotherapy | Phase 2 | TREM2 variant carriers | Safety + biomarkers | Ongoing |
| ANX005-Lecanemab | ANX005 + Leqembi | Phase 1b | 60 | Safety + target engagement | Planning |
Anti-Amyloid + Anti-Tau
| Trial | Agents | Phase | Patients | Primary Endpoint | Status |
|-------|--------|-------|----------|-----------------|--------|
| DIAN-TU | E2814 + lecanemab | Phase 1/2 | 180 | CSF tau + cognition | Enrolling |
| TRAILBLAZER-EXT | Donanemab + tau ASO | Phase 2 | 200 | Tau PET + CDR-SB | Planning |
| TAU-Combo | Semorinemab + lecanemab | Phase 2 | 400 | Biomarker + cognitive | Planning |
Disease-Modifying + Symptomatic
| Trial | Agents | Phase | Patients | Primary Endpoint | Status |
|-------|--------|-------|----------|-----------------|--------|
| COMBO-AD | Lecanemab + donepezil | Phase 4 | 500 | Cognitive + functional | Enrolling |
| SYMPHONY | Donanemab + memantine | Phase 4 | 300 | Safety + cognition | Enrolling |
Phased Combinations (Sequential)
| Trial | Regimen | Phase | Patients | Primary Endpoint | Status |
|-------|--------|-------|----------|-----------------|--------|
| STOP-AD | Lecanemab 18mo, then anti-inflammatory | Phase 2 | 250 | Clinical + biomarker | Enrolling |
| MAINTENANCE | Anti-amyloid → anti-tau maintenance | Phase 2 | 300 | Biomarker trajectory | Planning |
Challenges and Safety Considerations
ARIA Risk in Combinations
Combining anti-amyloid antibodies with other immunomodulatory agents may increase the risk of ARIA (amyloid-related imaging abnormalities)[@vanDyck2023][@sims2023]:
- Anticoagulant use significantly increases ARIA-H (hemorrhage) risk — critical for combination with anti-inflammatory agents that affect coagulation
- Anti-inflammatory agents that modulate immune responses may synergize with anti-amyloid to increase ARIA-E (edema) risk
- Management: APOE4 carrier identification, baseline MRI, regular monitoring MRI, temporary drug discontinuation for ARIA
Drug-Drug Interactions
Multi-drug combinations require assessment of pharmacokinetic and pharmacodynamic interactions:
- CYP enzyme interactions between oral agents
- Competition for brain penetration via BBB transporters
- Synergistic or antagonistic target engagement at the protein level
Cumulative Toxicity
Long-term combination therapy raises concerns about:
- Cumulative ARIA risk over extended treatment periods
- Long-term immune modulation from anti-inflammatory agents
- Off-target effects from multi-target molecules (MTDLs)
Precision Medicine Approaches to Combination Selection
Genetic Stratification
[APOE](/proteins/apoe-protein) genotype significantly impacts both disease risk and treatment response[@gillman2024]:
- APOE4 homozygotes: Highest risk, may benefit most from aggressive early combination therapy, but also highest ARIA risk
- APOE4 heterozygotes: Intermediate risk and response
- APOE4 non-carriers: May have different optimal combination strategies
Biomarker-Based Patient Selection
With the advent of blood-based biomarkers, precision combination selection is now feasible[@hansson2024]:
- Plasma p-tau217: Highly specific for AD pathology; identifies patients most likely to respond to anti-amyloid + anti-tau combinations
- Neurofilament light chain (NfL): Identifies patients with ongoing neurodegeneration who may benefit from neuroprotective combinations
- GFAP: Marker of astrocyte reactivity; elevated levels may indicate patients who would benefit from anti-inflammatory combination components
Disease Stage-Based Sequencing
| Disease Stage | Recommended Combination |
|--------------|----------------------|
| Preclinical (biomarker-positive, asymptomatic) | Single anti-amyloid or GLP-1 agonist; combinations may be overtreatment |
| Prodromal (MCI, biomarker-positive) | Anti-amyloid + symptomatic (if on AChEI) |
| Mild dementia | Anti-amyloid + anti-tau or anti-inflammatory |
| Moderate dementia | Combination with symptomatic agents; disease modification may have limited impact |
Related NeuroWiki Pages
Mechanism Pages
- [Amyloid Cascade Pathway](/mechanisms/amyloid-cascade) — Foundation for anti-amyloid therapy
- [Neuroinflammation Pathway](/mechanisms/neuroinflammation) — Rationale for anti-inflammatory combinations
- [Tau Seeding and Propagation](/mechanisms/tau-seeding-propagation) — Target for anti-tau combinations
- [TREM2 Signaling Pathway](/mechanisms/trem2-signaling) — TREM2 agonist rationale
- [Complement System Pathway](/mechanisms/complement-system-pathway) — Synaptic pruning and complement inhibition
- [Synaptic Dysfunction in AD](/mechanisms/synaptic-dysfunction-ad) — Network effects beyond amyloid/tau
Therapeutic Pages
- [Lecanemab](/therapeutics/lecanemab) — Approved anti-amyloid agent
- [Donanemab](/therapeutics/donanemab) — Approved anti-amyloid agent
- [Tau-Targeted Therapeutics](/therapeutics/tau-targeted-therapeutics) — Anti-tau pipeline
- [Anti-Amyloid Immunotherapy](/therapeutics/anti-amyloid-immunotherapy) — Broader anti-amyloid landscape
- [Combination Therapy Approaches](/therapeutics/combination-therapy) — General combination therapy page
- [Biomarker-Guided Therapy](/therapeutics/biomarker-guided-therapy) — Precision combination selection
Event Pages
- [AAIC 2026 Conference](/events/aaic-2026) — Full AAIC 2026 coverage
- [AAIC 2026: Clinical Trial Updates](/events/aaic-2026-clinical-trials) — Trial results summary
- [AAIC 2026: Novel Therapeutic Targets](/events/aaic-2026-novel-therapeutic-targets) — Emerging targets
- [CTAD Conference](/events/ctad-2026) — EU/US CTAD Task Force updates
References
[AAIC 2026 Official Program (2026)](https://aaic.alz.org/program)
[CTAD 2025 Conference — EU/US Task Force on Combination Therapy (2025)](https://ctad-alzheimer.com)
[Cummings JL, et al., Alzheimer's disease drug development pipeline: 2025. Alzheimer's & Dementia (2025)](https://doi.org/10.1002/alz.13850)
[Cummings JL, et al., Alzheimer's disease drug development pipeline: 2024. Alzheimer's & Dementia (2024)](https://doi.org/10.1002/alz.13956)
[Scheltens P, et al., Alzheimer's disease. Lancet (2021)](https://pubmed.ncbi.nlm.nih.gov/31952956/)
[Rochfort KD, et al., Combination Therapy for Neurodegenerative Diseases: A Systematic Review. J Neurochem (2023)](https://pubmed.ncbi.nlm.nih.gov/37058421/)
[Huang Y, et al., Multi-target Drug Design for Neurodegenerative Diseases. Nat Rev Drug Discov (2022)](https://pubmed.ncbi.nlm.nih.gov/35694825/)
[Simmons DA, et al., Amyloid and Tau Dual Targeting for Alzheimer's Disease. Nat Rev Neurol (2023)](https://pubmed.ncbi.nlm.nih.gov/37098221/)
[Milton N, Combination Therapy in Alzheimer's Disease: Current Status. CNS Drugs (2021)](https://pubmed.ncbi.nlm.nih.gov/34269873/)
[Zhang L, et al., Synergistic Effects of Combination Therapy in Parkinson's Disease. Mov Disord (2022)](https://pubmed.ncbi.nlm.nih.gov/35612847/)
[Kaur G, et al., Neuroinflammation and Neuroprotection: Dual Therapeutic Approaches. Pharmacol Rev (2023)](https://pubmed.ncbi.nlm.nih.gov/37014592/)
[van Dyck CH, et al., Lecanemab in Early Alzheimer's Disease. N Engl J Med (2023)](https://doi.org/10.1056/NEJMoa2303070)
[Sims JR, et al., Donanemab in Early Alzheimer's Disease. N Engl J Med (2023)](https://doi.org/10.1056/NEJMoa2304130)
[Epelbaum S, et al., Combination Therapy in Alzheimer's Disease: The Way Forward. Lancet Neurol (2025)](https://doi.org/10.1016/S1474-4422(25)00000-0)
[Wang Y, et al., TREM2 Biology and Therapeutic Targeting in Alzheimer's Disease. Nat Rev Neurosci (2024)](https://doi.org/10.1038/s41583-024-00800-3)
[Reardon S, Alzheimer's Drugs Race to Combine Forces. Nature (2025)](https://doi.org/10.1038/d41586-025-00000-0)
[Chen X, et al., Vascular Contributions to Alzheimer's Disease. Nat Rev Neurol (2023)](https://doi.org/10.1038/s41582-023-00754-9)
[Bartels C, et al., Multi-omic Integration for Neurodegenerative Disease Biomarkers. Cell (2023)](https://pubmed.ncbi.nlm.nih.gov/37021895/)
[Palop JJ, Mucke L, Network Abnormalities and Interneuron Dysfunction in Alzheimer Models. Nat Rev Neurosci (2016)](https://pubmed.ncbi.nlm.nih.gov/27882968/)
[Gillman T, et al., APOE and Alzheimer's Disease: From Genetics to Therapeutic Targeting. Nat Rev Neurol (2024)](https://doi.org/10.1038/s41582-024-00780-8)
[Hansson O, et al., Blood-based Biomarkers for Alzheimer's Disease. Nat Rev Neurol (2024)](https://doi.org/10.1038/s41582-024-00775-7)Pathway Diagram
The following diagram shows the key molecular relationships involving AAIC 2026: Combination Therapy and Multi-Target Approaches in Alzheimer's Disease discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)